IFIT1 antibody is human, mouse and rat reactive. At least three isoforms of IFIT1 are known to exist. This antibody is predicted to not cross-react with other members of the IFIT protein family.
Purification
IFIT1 antibody is affinity chromatography purified via peptide column.
Immunogène
IFIT1 antibody was raised against an 18 amino acid peptide near the carboxy terminus of human IFIT1. The immunogen is located within amino acids 290 - 340 of IFIT1.
IFIT1
Reactivité: Humain
WB
Hôte: Lapin
Polyclonal
unconjugated
Indications d'application
IFIT1 antibody can be used for detection of IFIT1 by Western blot at 1 - 2 μ,g/mL. Antibody can also be used for Immunohistochemistry at 5 μ,g/mL. For Immunoflorescence start at 20 μ,g/mL.
Antibody validated: Western Blot in rat samples, Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Restrictions
For Research Use only
Format
Liquid
Concentration
1 mg/mL
Buffer
IFIT1 Antibody is supplied in PBS containing 0.02 % sodium azide.
Agent conservateur
Sodium azide
Précaution d'utilisation
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Stock
-20 °C,4 °C
Stockage commentaire
IFIT1 antibody can be stored at 4°C for three months and -20°C, stable for up to one year.
Antigène
IFIT1
(Interferon-Induced Protein with Tetratricopeptide Repeats 1 (IFIT1))
The interferon-induced protein with tetratricopeptide repeats 1 (IFIT1) protein is a member of a family of tetratricopeptide repeat-containing proteins whose transcription is upregulated by interferons, virus infection, and molecular patterns such as dsRNA or lipopolysaccharides (1,2). These proteins have been suggested to induce anti-viral cellular activities in response to infection (2). Together with the interferon-induced transmembrane protein 1 (IFITM1), IFIT1 inhibits the replication of the Hepatitis C virus, suggesting that it may be useful in the development of therapeutic treatments (3).